shutterstock_1425740486_ii_studio
II Studio / Shutterstock.com
24 July 2019AmericasRory O'Neill

Gilead licenses HIV injections for $25m

Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
9 May 2019   A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.

More on this story

Americas
9 May 2019   A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.

More on this story

Americas
9 May 2019   A generic version of Gilead’s Truvada will hit the market in 2020, a year earlier than expected.